Park Medi World IPO Details
Park Medi World IPO Summary
Park Medi World IPO opens for subscription on 10 Dec 2025 and closes on 12 Dec 2025.The IPO will be listed on NSE, BSE with the tentative listing date set for 17 Dec 2025.
Park Medi World IPO price band has been fixed at ₹154 – ₹162 per share. The face value is ₹2 per share with a lot size of 92.
Park Medi World IPO total issue size comprises 5,67,90,123 shares (aggregating up to ₹920.00 Cr.). This includes a fresh issue of 4,75,30,864 shares (aggregating up to ₹770.00 Cr.). Offer for Sale consists of 92,59,259 shares (aggregating up to ₹150.00 Cr.). Pre-issue shareholding stands at 38,43,99,990, which will increase to 43,19,30,854 post-issue.
Park Medi World IPO carries a ₹0 (0%) GMP, reflecting investor sentiment.
Park Medi World IPO Lot Size :Retail Minimum is 1 lot (92 shares) amounting to ₹14,904. Retail Maximum is 13 lots (1,196 shares) amounting to ₹193,752. SHNI Minimum is 14 lots (1,288 shares) amounting to ₹208,656. SHNI Maximum is 67 lots (6,164 shares) amounting to ₹998,568. BHNI Minimum is 68 lots (6,256 shares) amounting to ₹1,013,472.
The Lead Managers for Park Medi World IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Nuvama Wealth Management Ltd, Clsa India Pvt Ltd, Dam Capital Advisors Ltd, Intensive Fiscal Services Pvt Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For detailed information, Refer to the Park Medi World Limited RHP.
Park Medi World IPO Details
Park Medi World IPO Subscription
Park Medi World IPO Application Wise Breakup (Approx)
Park Medi World IPO Dates
- 10 Dec 2025Opening dateOpen
- 12 Dec 2025Closing dateClose
- 15 Dec 2025Allotment Date Allotment
- 16 Dec 2025Initiation of RefundsRefund
- 16 Dec 2025Credit of SharesCredit
- 17 Dec 2025Listing dateListing
Park Medi World IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 92 | ₹14,904 |
| Retail Maximum | 13 | 1196 | ₹193,752 |
| SHNI Minimum | 14 | 1288 | ₹208,656 |
| SHNI Maximum | 67 | 6164 | ₹998,568 |
| BHNI Minimum | 68 | 6256 | ₹1,013,472 |
Park Medi World IPO Reservation
Promoter Holding
Documents
Park Medi World IPO Valuations
Park Medi World Financial Information
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 2,018.74 | 1,912.10 | 1,592.83 | 1,293.23 |
| Total Income | 707.45 | 1,263.08 | 1,272.18 | 1,093.96 |
| Profit After Tax | 112.89 | 152.01 | 228.19 | 199.38 |
| EBITDA | 189.62 | 310.30 | 390.34 | 343.71 |
| NET Worth | 815.98 | 667.55 | 437.77 | |
| Reserves and Surplus | 913.13 | 805.92 | 609.68 | 379.91 |
| Total Borrowing | 648.96 | 686.71 | 575.68 | 517.42 |
| Amount in ₹ Crore | ||||
About Park Medi World IPO
Incorporated in 2011, Park Medi World Limited is a private healthcare services provider operating a network of multi–super speciality hospitals across North India. As of September 30, 2024, the company manages a total capacity of 3,000 beds across its hospitals.
The company operates 13 multi–super speciality hospitals under the Park brand, all accredited by the National Accreditation Board for Hospitals & Healthcare Providers (NABH). Additionally, seven hospitals hold NABL accreditation for diagnostic and laboratory services, reinforcing the group’s focus on clinical quality and patient safety. Park Medi World’s network spans key locations across Haryana, Delhi, Punjab, and Rajasthan.
Park Hospitals collectively offer 30+ super speciality and speciality services, including internal medicine, neurology, urology, gastroenterology, general surgery, orthopaedics, oncology, and other high-acuity disciplines. As of the stated date, the company’s infrastructure includes 805 ICU beds, 63 operating theatres (OTs), two dedicated cancer care units, and oxygen generation plants at every hospital, enhancing operational reliability and critical-care readiness.
The hospital network is present in several major cities, including Ambala, Gurugram, Karnal, Panipat, Palam Vihar, Sonipat, Faridabad, Delhi, Patiala, Mohali, Jaipur, and Behror, providing broad regional access across North India.
Operational Performance:
- Key Facilities Snapshot:
- 13 NABH-accredited hospitals
- 7 NABL-accredited hospitals
- 3,000 beds, including 805 ICU beds
- 63 Operating Theatres
- 2 dedicated cancer units
- Oxygen generation plants at all hospitals
As of September 30, 2024, Park Medi World Limited employed a total workforce of 5,235 personnel, including 891 doctors, 1,912 nurses, 671 medical professionals, and 1,761 support staff, enabling the company to operate its multi–super speciality network at scale and maintain consistent clinical quality across locations.
Strength Of Park Medi World IPO
- Second largest chain of private hospitals in North India and largest private hospital chain in Haryana.
- Delivering high-quality and affordable healthcare with a diverse specialty mix.
- Track record of successfully acquiring and integrating hospitals.
- Strong operational and financial performance with diversified payor mix.
- Doctor led professional management team with industry experience.
Risk Of Park Medi World IPO
- We are highly dependent on doctors, nurses, medical professionals and support staff. If we are unable to retain or attract such professionals, our business, results of operations and financial condition may be adversely affected.
- A significant portion of our revenue from operations is derived from our hospitals located in Haryana, which comprised 74.62%, 76.92%, 83.91% and 84.98% of our revenue from operations in the six months ended September 30, 2024 and Fiscals 2024, 2023 and 2022, respectively. Any adverse developments at these hospitals or in this state could have an adverse effect on our business, results of operations and financial condition.
- The nature of our business involves certain high costs including our cost of materials purchased, employee benefit expenses and professional and consultancy fees, and a failure to pass on such costs to patients could adversely affect our business, results of operations and financial condition.
- We may not be able to complete or achieve the expected benefits from current or future acquisitions or successfully integrate new hospitals with our network, which could adversely affect our business and prospects.
- We may not be successful in developing our proposed hospitals and may not achieve operating capacities that we anticipate, any of which could adversely affect our business, results of operations, financial condition and prospects.
- Our arrangements with certain of our doctors are on a consultancy basis. If such doctors discontinue their association with us or are unable to provide their services at our hospitals, our business and results of operations may be adversely affected.
- Certain of our Subsidiaries have experienced losses during the six months ended September 30, 2024 and the last three Fiscals. We cannot guarantee that these Subsidiaries will generate profits or avoid losses in the future.
- We generate a significant portion of our revenues from certain key specialties such as internal medicine, neurology, urology, gastroenterology, cardiology, general surgery and orthopedics, which together contributed 92.17%, 92.87%, 92.42% and 90.39% of our revenue from operations for the six months ended September 30, 2024 and Fiscals 2024, 2023 and 2022, respectively. Any adverse developments in the demand or income from such specialties may adversely affect our business, results of operations and financial condition.
- We are dependent on revenue generated from our in-patient department. If we are unable to maintain or increase our hospital occupancy rates at sufficient levels and generate adequate returns on our capital expenditure, our operating efficiencies and profitability may be adversely affected.
- A significant portion of our revenue is derived from payments made by government agencies and insurance providers under various healthcare schemes. Delays in receiving payments or the rejection of claims raised by us could adversely impact our business, results of operations, financial condition and cash flows.
Objectives Park Medi World IPO
1. Repayment/ prepayment, in full or in part, of certain outstanding borrowings availed by the Company and certain of the Subsidiaries.
2. Funding capital expenditure for development of new hospital and expansion of existing hospital by our certain Subsidiaries Park Medicity (NCR) and Blue Heavens, respectively.
3. Funding capital expenditure for purchase of medical equipment by the Company and our certain Subsidiaries, Blue Heavens and Ratangiri.
4. Unidentified inorganic acquisitions and general corporate purposes.
Company Contact Details
Park Medi World Ltd.
12, Meera Enclave Near Keshopur,
Bus Depot, Outer Ring Road,
New Delhi, New Delhi, 110018
Phone: + 91 124 696 000
Email: company.secretary@parkhospital.in
Website: http://www.parkhospital.in/
Registrar Contact Details
Park Medi World FAQs
The Park Medi World IPO is a MAINBOARD public issue comprising 56790123 equity shares with a face value of ₹2 each, aggregating to a total issue size of ₹920.00 Cr.. The issue price has been fixed at ₹162 per equity share, and the minimum application size is 92 shares.
The IPO opens for subscription on 10 Dec 2025, and closes on 12 Dec 2025.
Kfin Technologies Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
As of now, the current GMP stands at ₹0 (0%).
Quick Links
Comments
